Drugs / Ticarcillin-Clavulanic Acid
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT01229046 Comparator | Sep 2010 → ? | infectious disease with sepsis | Phillip Brian Smith | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT02800785 Comparator | May 2016 → Mar 2020 | appendicitis | University of Washington | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ticarcillin-clavulanic acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01229046 ↗ |
| Known as | ticarcillin-clavulanate | “Ticarcillin-clavulanate is a sterile injectable antibacterial combination consisting of the semisynthetic antibiotic ticarcillin disodium, and the β-lactamase inhibitor...” NCT01229046 ↗ |
| Action | Inhibit | “possesses the ability to inactivate a wide variety of β-lactamases by blocking the active sites of these enzymes” NCT01229046 ↗ |
| Modality | Small molecule | “the semisynthetic antibiotic ticarcillin disodium, and the β-lactamase inhibitor clavulanate potassium” NCT01229046 ↗ |
| Route | Intravenous | “for intravenous administration” NCT01229046 ↗ |